Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / MYO5A

MYO5A

Basics

Aliases:
This biomarker is also known as:
  • Myosin heavy chain 12,
  • myosin V,
  • unconventional myosin-Va,
  • Myosin-12,
  • MYR12,
  • dilute myosin heavy chain, non-muscle,
  • myosin VA (heavy chain 12, myoxin),
  • MYO5,
  • Myoxin,
  • myoxin,
  • myosin-12,
  • Dilute myosin heavy chain, non-muscle,
  • myosin VA (heavy polypeptide 12, myoxin),
  • myosin, heavy polypeptide kinase,
  • myosin-Va,
  • MYH12,
  • GS1,

View in BioMuta

Description…

The MYO5A gene is one of three myosin V heavy-chain genes, belonging to the myosin gene superfamily. The MYO5A protein functions as a processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament. MYO5A is also involved in cytoplasmic vesicle transport and anchorage, spindle-pole alignment and mRNA translocation. Different isoforms, encoded by alternatively spliced transcript variants, have been reported.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

MYO5A was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html